By Cecilia Butini 

Roche Holding AG said Friday that the European Medicines Agency's Committee for Medicinal Products for Human Use has issued an opinion supporting the use of the REGN-COV2 antibody cocktail proposed for the treatment of Covid-19 patients.

The committee's opinion was produced as the European Medicines Agency carries out its rolling review process of the treatment, which is used to speed up the formal marketing application for the drug and which can be done during a public health emergency, Roche said. The cocktail is made of casirivimab and imdevimab, two monoclonal antibodies.

The Swiss pharma major is developing the antibody cocktail together with partner Regeneron Pharmaceuticals Inc, and the two companies plan to have more than two million doses available in 2021, Roche said.


Write to Cecilia Butini at


(END) Dow Jones Newswires

February 26, 2021 07:50 ET (12:50 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.